Hemocompatibility of new magnetically-levitated centrifugal pump technology compared to the CentriMag adult pump

Schibilsky, David; Takatani, Setsuo; Schibilsky, Barbara; Graf, Tobias; Silva, Diana Michels da; Wendel, Hans Peter; Avci‐Adali, Meltem; Schlensak, Christian

doi:10.1038/s41598-020-78709-0

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased activation of coagulation, which is sensitively indicated by elevated TAT concentrations [ 51 ], is known in patients with LVADs and was previously described in various clinical studies [ 15 , 52 , 53 ]. In accordance with previous experimental LVAD studies [ 54 , 55 ] utilizing an in vitro test circuit, our study likewise demonstrated a time-dependent activation of the coagulation system. Nevertheless, TAT concentrations did not significantly differ between both groups.…”

Section: Discussionsupporting

confidence: 92%

Comparison of the Hemocompatibility of an Axial and a Centrifugal Left Ventricular Assist Device in an In Vitro Test Circuit

Borchers

Winnersbach

Kraemer

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Hemocompatibility of left ventricular assist devices is essential for preventing adverse events. In this study, we compared the hemocompatibility of an axial-flow (Sputnik) to a centrifugal-flow (HeartMate 3) pump. Methods: Both pumps were integrated into identical in vitro test circuits, each filled with 75 mL heparinized human blood of the same donor. During each experiment (n = 7), the pumps were operated with equal flow for six hours. Blood sampling and analysis were performed on a regular schedule. The analytes were indicators of hemolysis, coagulation activation, platelet count and activation, as well as extracellular vesicles. Results: Sputnik induced higher hemolysis compared to the HeartMate 3 after 360 min. Furthermore, platelet activation was higher for Sputnik after 120 min onward. In the HeartMate 3 circuit, the platelet count was reduced within the first hour. Furthermore, Sputnik triggered a more pronounced increase in extracellular vesicles, a potential trigger for adverse events in left ventricular assist device application. Activation of coagulation showed a time-dependent increase, with no differences between both groups. Conclusions: This experimental study confirms the hypothesis that axial-flow pumps may induce stronger hemolysis compared to centrifugal pumps, coming along with larger amounts of circulating extracellular vesicles and a stronger PLT activation.

show abstract

Section: Discussionsupporting

confidence: 92%

Comparison of the Hemocompatibility of an Axial and a Centrifugal Left Ventricular Assist Device in an In Vitro Test Circuit

Borchers

Winnersbach

Kraemer

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…The variable coefficient of NIH and MIH could be acceptable as in other certified labs. The hemolysis results of commercial pumps were consistent with the data in the literature ( Hijikata et al, 2008 ; Schibilsky et al, 2020 ). MoyoAssist ® and CentriMag demonstrated lower hemolysis levels might be due to their non-contacting bearings associated with lower shear stress in pumps.…”

Section: Discussionsupporting

confidence: 89%

A comprehensive comparison of the in vitro hemocompatibility of extracorporeal centrifugal blood pumps

Li,

Mei,

et al. 2023

Front. Physiol.

View full text Add to dashboard Cite

Purpose: Blood damage has been associated with patients under temporary continuous-flow mechanical circulatory support. To evaluate the side effects caused by transit blood pumping, in vitro hemocompatibility testing for blood damage in pumps is considered a necessary reference before clinical trials.Methods: The hemocompatibility of five extracorporeal centrifugal blood pumps was investigated comprehensively, including four commercial pumps (the Abbott CentriMag, the Terumo Capiox, the Medos DP3, and the Medtronic BPX-80) and a pump in development (the magAssist MoyoAssist®). In vitro, hemolysis was tested with heparinized porcine blood at nominal operating conditions (5 L/min, 160 mmHg) and extreme operating conditions (1 L/min, 290 mmHg) using a circulation flow loop. Hematology analyses concerning the blood cell counts and the degradation of high-molecular-weight von Willebrand factor (VWF) during 6-h circulation were also evaluated.Results: Comparing the in vitro hemocompatibility of blood pumps at different operations, the blood damage was significantly more severe at extreme operating conditions than that at nominal operating conditions. The performance of the five blood pumps was arranged in different orders at these two operating conditions. The results also demonstrated superior hemocompatibility of CentriMag and MoyoAssist® at two operating conditions, with overall low blood damage at hemolysis level, blood cell counts, and degradation of high-molecular-weight VWF. It suggested that magnetic bearings have an advantage in hemocompatibility compared to the mechanical bearing of blood pumps.Conclusion: Involving multiple operating conditions of blood pumps in in vitro hemocompatibility evaluation will be helpful for clinical application. In addition, the magnetically levitated centrifugal blood pump MoyoAssist® shows great potential in the future as it demonstrated good in vitro hemocompatibility.

show abstract

“…Nevertheless, the device does not include a portable heater/cooler unit or other features that could support the treatment during ECPR. Magnetically levitated pumps, such as contained by the Colibrì, reduce hemolysis, 9 which is beneficial, especially for patients on long‐term support.…”

Section: Discussionmentioning

confidence: 99%

First experience with the new extracorporeal membrane oxygenation system Colibrì

Saemann,

Stiller,

Willsch

et al. 2023

Artificial Organs

View full text Add to dashboard Cite

IntroductionExtracorporeal membrane oxygenation (ECMO) is increasingly used for circulatory or pulmonary support not only in‐hospital but also out‐of‐hospital. Small dimensions and a lightweight design are important, especially for out‐of‐hospital use but also for intra‐hospital transportation of patients who require ECMO support. We share our first experience with the new Colibrì ECMO system.Patients and MethodsFrom December 2022 to January 2023, we used the new Colibrì extracorporeal circulation (ECC) system in six patients with cardiac or pulmonary failure.ResultsThe Colibrì system was used in‐hospital in six patients with post‐cardiac surgery low output syndrome, respiratory failure due to influenza or acute respiratory distress syndrome, cardiogenic shock, pulmonary embolism, and failed weaning from cardiopulmonary bypass. The system was implanted in venovenous (VV) and venoarterial (VA) fashion in 3 patients, respectively. In one patient, the configuration was switched from VA to VV after cardiac recovery. One patient received left‐ventricular unloading using the IMPELLA®5.5. ECMO run time was 1 to 13 days. We did not notice any ECC system‐associated complications. No ECMO system changes were required.ConclusionOur case series concludes that the new Colibrì system is safe and effective for in‐hospital ECMO indications. The small dimensions and lightweight design are very beneficial for the transportation of patients. It might be especially helpful for out‐of‐hospital situations.

show abstract

Hemocompatibility of new magnetically-levitated centrifugal pump technology compared to the CentriMag adult pump

Cited by 5 publications

References 23 publications

Comparison of the Hemocompatibility of an Axial and a Centrifugal Left Ventricular Assist Device in an In Vitro Test Circuit

Comparison of the Hemocompatibility of an Axial and a Centrifugal Left Ventricular Assist Device in an In Vitro Test Circuit

A comprehensive comparison of the in vitro hemocompatibility of extracorporeal centrifugal blood pumps

First experience with the new extracorporeal membrane oxygenation system Colibrì

Contact Info

Product

Resources

About